NASDAQ$CNTA
Centessa Pharmaceuticals plc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Centessa reported financial results and business highlights.
Centessa Pharmaceuticals reported its third quarter 2023 financial results, with a net loss of $38.6 million. The company's cash, cash equivalents, and short-term investments totaled $281.3 million, expected to fund operations into 2026.
- Registrational PRESent-2 and PRESent-3 studies are ongoing for SerpinPC in hemophilia B.
- New data from Phase 2a study of SerpinPC accepted for poster presentation at ASH in December 2023.
- Preclinical data for ORX750 presented at World Sleep Congress, advancing in IND-enabling studies, with clinical proof of concept data planned for 2024.
- Ongoing Phase 1/2a study of LB101 (PD-L1xCD47) for the treatment of solid tumors.
Headline financials
Revenue & EPS history
Centessa · Revenue · Quarterly
$0
Forward guidance
Centessa Pharmaceuticals is focused on advancing its pipeline, including SerpinPC for hemophilia B, LB101 for solid tumors, and ORX750 for narcolepsy and other sleep-wake disorders. The company anticipates data presentations and clinical trial initiations in the near term.
Tailwinds
- Registrational PRESent-2 and PRESent-3 studies are ongoing for SerpinPC in hemophilia B.
- Data from Part 5 of the ongoing Phase 2a study accepted for poster presentation at ASH on December 10, 2023.
- Phase 1/2a first-in-human clinical study is ongoing for PD-L1xCD47 LockBody LB101.
- LB206 is a development candidate.
- The Company is focused on rapidly advancing ORX750 through IND-enabling studies, obtaining IND clearance and initiating clinical development with the goal of sharing clinical proof of concept data in sleep-deprived healthy volunteers in 2024.
Headwinds
- There are risks related to the safety and tolerability profile of product candidates.
- The company's ability to identify, screen and recruit a sufficient number of subjects in studies or clinical trials within anticipated timelines.
- Ability to execute IND-enabling activities in a timely manner or at all, including with respect to ORX750 and LB206.
- The company's ability to protect and maintain its intellectual property position.
- Economic risks to the United States and United Kingdom banking systems.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+1.0%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+4.0%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+19.4%
Q2 2024
Best reaction
-14.6%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.1% | -0.3% | +0.3% | |
| Q4 2025 | -4.2% | +6.1% | +45.9% | |
| Q3 2025 | -5.2% | -5.9% | +26.0% | |
| Q1 2025 | -1.2% | -1.6% | -0.6% | |
| Q4 2024 | -4.9% | -12.3% | -18.2% | |
| Q3 2024 | +8.1% | -4.4% | +0.8% | |
| Q2 2024 | +19.4% | +18.5% | +43.1% | |
| Q1 2024 | +0.8% | -1.1% | +8.1% | |
| Q4 2023 | -0.2% | +2.1% | -19.6% | |
| Q3 2023 | +6.8% | +13.4% | +7.1% | |
| Q2 2023 | +3.6% | -4.2% | +1.0% | |
| Q1 2023 | +0.2% | +0.9% | -0.4% | |
| Q4 2022 | -1.3% | -3.1% | +21.0% | |
| Q3 2022 | +5.3% | +4.7% | +15.1% | |
| Q2 2022 | -14.6% | -22.4% | -19.4% | |
| Q1 2022 | +2.0% | -15.7% | -21.1% | |
| Q4 2021 | -0.2% | +9.6% | -3.0% | |
| Q3 2021 | +2.5% | +9.3% | -9.9% | |
| Q1 2021 | +1.7% | +3.4% | +2.1% | |
| Q2 2021 | +1.7% | +3.4% | +2.1% | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro